Vestmark Advisory Solutions Inc. Makes New $15.54 Million Investment in UiPath Inc. (NYSE:PATH)

Vestmark Advisory Solutions Inc. acquired a new position in shares of UiPath Inc. (NYSE:PATH - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 625,740 shares of the healthcare company's stock, valued at approximately $15,543,000. UiPath accounts for approximately 0.8% of Vestmark Advisory Solutions Inc.'s portfolio, making the stock its 27th largest position. Vestmark Advisory Solutions Inc. owned approximately 0.11% of UiPath at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. HighMark Wealth Management LLC bought a new stake in shares of UiPath in the fourth quarter valued at approximately $27,000. Cypress Capital Management LLC WY bought a new stake in UiPath during the fourth quarter worth $29,000. Fifth Third Bancorp lifted its stake in UiPath by 2,005.3% during the third quarter. Fifth Third Bancorp now owns 2,000 shares of the healthcare company's stock worth $34,000 after purchasing an additional 1,905 shares during the last quarter. GAMMA Investing LLC bought a new stake in UiPath during the fourth quarter worth $36,000. Finally, FNY Investment Advisers LLC bought a new stake in UiPath during the fourth quarter worth $40,000. Institutional investors own 62.50% of the company's stock.

Insider Buying and Selling at UiPath

In other news, CFO Ashim Gupta sold 16,000 shares of the stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $22.84, for a total transaction of $365,440.00. Following the transaction, the chief financial officer now owns 87,505 shares of the company's stock, valued at approximately $1,998,614.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last quarter, insiders have sold 72,000 shares of company stock valued at $1,591,360. 31.03% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

PATH has been the subject of several recent analyst reports. Truist Financial restated a "buy" rating and set a $32.00 target price on shares of UiPath in a research note on Wednesday, March 20th. Bank of America upped their target price on UiPath from $26.00 to $30.00 and gave the stock a "buy" rating in a research note on Thursday, March 14th. Wells Fargo & Company upped their target price on UiPath from $24.00 to $25.00 and gave the stock an "equal weight" rating in a research note on Thursday, March 14th. DA Davidson upped their target price on UiPath from $20.00 to $24.00 and gave the stock a "neutral" rating in a research note on Thursday, March 14th. Finally, JPMorgan Chase & Co. upgraded shares of UiPath from a "neutral" rating to an "overweight" rating and upped their price target for the stock from $22.00 to $28.00 in a report on Thursday, March 14th. Nine investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $27.41.

UiPath Price Performance

NYSE PATH traded up $0.18 on Friday, reaching $19.48. The company had a trading volume of 3,862,423 shares, compared to its average volume of 5,757,008. The firm has a market cap of $11.08 billion, a price-to-earnings ratio of -114.58 and a beta of 1.01. UiPath Inc. has a fifty-two week low of $12.38 and a fifty-two week high of $27.87. The business has a 50 day moving average of $21.75 and a two-hundred day moving average of $21.72.

UiPath (NYSE:PATH - Get Free Report) last issued its quarterly earnings results on Wednesday, March 13th. The healthcare company reported $0.06 EPS for the quarter, beating analysts' consensus estimates of ($0.04) by $0.10. The business had revenue of $405.25 million for the quarter, compared to analysts' expectations of $383.32 million. UiPath had a negative net margin of 6.87% and a negative return on equity of 3.29%. As a group, research analysts predict that UiPath Inc. will post -0.04 earnings per share for the current fiscal year.

UiPath Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.